TY  - JOUR
AU  - Michels, Sebastian
AU  - Massutí, Bartomeu
AU  - Schildhaus, Hans-Ulrich
AU  - Franklin, Jeremy
AU  - Sebastian, Martin
AU  - Felip, Enriqueta
AU  - Grohé, Christian
AU  - Rodriguez-Abreu, Delvys
AU  - Abdulla, Diana S Y
AU  - Bischoff, Helge
AU  - Brandts, Christian
AU  - Carcereny, Enric
AU  - Corral, Jesús
AU  - Dingemans, Anne-Marie C
AU  - Pereira, Eva
AU  - Fassunke, Jana
AU  - Fischer, Rieke N
AU  - Gardizi, Masyar
AU  - Heukamp, Lukas
AU  - Insa, Amelia
AU  - Kron, Anna
AU  - Menon, Roopika
AU  - Persigehl, Thorsten
AU  - Reck, Martin
AU  - Riedel, Richard
AU  - Rothschild, Sacha I
AU  - Scheel, Andreas H
AU  - Scheffler, Matthias
AU  - Schmalz, Petra
AU  - Smit, Egbert F
AU  - Limburg, Meike
AU  - Provencio, Mariano
AU  - Karachaliou, Niki
AU  - Merkelbach-Bruse, Sabine
AU  - Hellmich, Martin
AU  - Nogova, Lucia
AU  - Büttner, Reinhard
AU  - Rosell, Rafael
AU  - Wolf, Jürgen
PY  - 2019
DO  - 10.1016/j.jtho.2019.03.020
UR  - http://hdl.handle.net/10668/13819
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic efficacy of crizotinib in this subset has been shown in early phase trials in the United States and East Asia. Here we present data on efficacy and safety of a prospective phase...
LA  - en
KW  - Crizotinib
KW  - Lung cancer
KW  - ROS1
KW  - TP53
KW  - Targeted treatment
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Brain Neoplasms
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Crizotinib
KW  - Female
KW  - Follow-Up Studies
KW  - Gene Rearrangement
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Prognosis
KW  - Prospective Studies
KW  - Protein Kinase Inhibitors
KW  - Protein-Tyrosine Kinases
KW  - Proto-Oncogene Proteins
KW  - Response Evaluation Criteria in Solid Tumors
KW  - Survival Rate
TI  - Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
TY  - research article
VL  - 14
ER  -